ACT-385781A PAH Post-marketing study

A Post-marketing, Open-label-study ACT-385781A in patients with pulmonary arterial hypertension

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080222096

Enrollment

Registered

2013-06-03

Start date

2013-06-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension (PAH)

Interventions

investigational material(s) Generic name etc : ACT-385781A INN of investigational material : Epoprostenol Therapeutic category code : 219 Other cardiovascular agents Dosage and Administration for Inve

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: * PAH idiopathic * PAH heritable * PAH secondary to connective tissue or auto-immune diseases

Exclusion criteria

Exclusion criteria: Patients with respiratory and/or cardiovascular distress in need of emergency care, etc.

Design outcomes

Primary

Measure	Time frame
Changes in cardiopulmonary hemodynamics; mean pulmonary artery pressure, pulmonary vascular resistance, total pulmonary resistance, cardiac index, cardiac output, mean right atrial pressure, mixed venous oxygen saturation, pulmonary vascular resistance index Right Heart catheterization	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026